Collaborative Data Network Aster Insights leads ORIEN, a consortium of leading academic cancer centers, enabling access to large scale clinicogenomic data and the Total Cancer Care observational study. This positions the company to offer data driven biomarker discovery, real world evidence, and study design services to pharma and biotech partners.

Clinical Trial Acceleration The company specializes in accelerating the life cycle of oncology medical product development using scientific and clinical intelligence and strong partnerships across patients, academia, and industry to support faster trial design and startup.

Next Gen Panel The April 2023 launch of the AsterExome oncology panel with Twist Bioscience demonstrates capability to deliver advanced genomics tools for cancer research, creating a cross selling opportunity for panel based discovery, biomarker validation, and companion diagnostic development.

Strategic Leadership The May 2023 appointment of Dr Anand Shah as CEO signals a growth oriented strategy and provides a leadership driven narrative for engaging pharma and academic partners seeking long term collaboration.

Mid Market Focus With revenue in the 10 to 25 million range and 11 to 50 employees, Aster Insights targets mid market biotech partnerships and can scale data services, analytics, and informatics to complement growing company needs.